

## Hormone therapies in prostate cancer, less but better

Poster Session 67

Monday, 14 March  
12:15 - 13:45

**Location:** Room Stockholm (Hall B2, level 0)

**Chairs:** S. Bracarda, Perugia (IT)  
F. Calais Da Silva Junior, Lisbon (PT)  
J. Morote Robles, Barcelona (ES)

### Aims and objectives of this presentation

Hormone therapy remains the mainstay systemic treatment of advanced prostate cancer. Despite almost 60 years of use the optimal timing and modalities remain to be determined. This session will focus on recent updates.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (\*) are 3 minutes in length, followed by 3 minutes for discussion.

- \*843 **Phase III study of intermittent monotherapy versus continuous combined androgen deprivation**  
By: Calais Da Silva Junior F.<sup>1</sup>, Calais Da Silva Senior F.E.<sup>2</sup>, Gonçalves F.<sup>3</sup>, Kliment J.<sup>4</sup>, Santos A.<sup>5</sup>, Spyros P.<sup>6</sup>, Queimadelos A.<sup>7</sup>, Robertson C.<sup>8</sup>  
**Institutes:**<sup>1</sup>CHLC - Hospital De São José, Dept. of Urology, Lisbon, Portugal, <sup>2</sup>CHLC - H.S.José, Dept. of Urology, Lisbon, Portugal, <sup>3</sup>CUIMED A Saint Michal Hospital, Dept. of Urology, Bratislava, Slovakia, <sup>4</sup>Jessenius School of Medicine, Dept. of Urology, Martin, Slovakia, <sup>5</sup>Hospital De Braga, Dept. of Urology, Braga, Portugal, <sup>6</sup>Amalia Fleming Hospital, Dept. of Urology, Athens, Greece, <sup>7</sup>Policlinica La Rosaleda, Dept. of Urology, Santiago Compostela, Spain, <sup>8</sup>University of Strathclyde, Dept. of Statistics, Glasgow, United Kingdom
- \*844 **Survival outcomes in octogenarian and nonagenarian patients treated with first-line androgen deprivation therapy for localized prostate cancer**  
By: Dell'Oglio P.<sup>1</sup>, Bishr M.<sup>1</sup>, Boehm K.<sup>2</sup>, Trudeau V.<sup>1</sup>, Larcher A.<sup>3</sup>, Tian Z.<sup>4</sup>, Saad F.<sup>5</sup>, Capitanio U.<sup>3</sup>, Briganti A.<sup>3</sup>, Graefen M.<sup>2</sup>, Montorsi F.<sup>3</sup>, Karakiewicz P.<sup>1</sup>  
**Institutes:**<sup>1</sup>Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Dept. of Urology, Montreal, Canada, <sup>2</sup>Martini-Clinic, Prostate Cancer Center Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany, <sup>3</sup>Ircs Ospedale San Raffaele, Dept. of Oncology and Urology, Milan, Italy, <sup>4</sup>McGill University, Dept. of Epidemiology, Biostatistics and Occupational Health, Montreal, Canada, <sup>5</sup>University of Montreal Health Center, Dept. of Urology, Montreal, Canada
- \*845 **Timing of the development of metastasis and initiation of treatment are important prognostic factors in prostate cancer**  
By: Frees S., Akamatsu S., Lynch K., Chavez-Munoz C., Black P., Gleave M., Goldenberg L., Chi K., So A.  
**Institutes:**Vancouver Prostate Centre, Dept. of Urological Sciences, Vancouver, Canada
- \*846 **Peri-prostatic fat volume predicts castration resistance in advanced prostate cancer**  
By: Hendry J.<sup>1</sup>, Patel A.<sup>2</sup>, Leung H.<sup>1</sup>, Salji M.<sup>1</sup>  
**Institutes:**<sup>1</sup>Beatson Institute For Cancer Research, Dept. of Urology, Glasgow, United Kingdom, <sup>2</sup>Queen Elizabeth University Hospital, Dept. of Radiology, Glasgow, United Kingdom
- \*847 **Impact of free testosterone levels on the outcome of androgen deprivation therapy in metastatic prostate cancer**  
By: Mandhani A., Agnihotri S., Singh R.  
**Institutes:**Sanjay Gandhi Post Graduate Institute of Medical Sciences, Dept. of Urology, Lucknow, India

- \*848 **Degarelix is well tolerated and effective for the treatment of prostate cancer: Results from a phase III study in China**  
**By:** Xie L.<sup>1</sup>, Bosnyák Z.<sup>2</sup>, Sun Y.<sup>3</sup>, Malmberg A.<sup>2</sup>, Neijber A.<sup>2</sup>, Fen W.X.<sup>4</sup>  
**Institutes:**<sup>1</sup>The First Affiliated Hospital of College of Medicine, Zhejiang University School of Medicine, Dept. of Urology, Zhejiang Province, China, <sup>2</sup>Ferring Pharmaceuticals A/S, Dept. of Global Clinical Research and Development, Copenhagen, Denmark, <sup>3</sup>Changhai Hospital The First Affiliated Hospital of The Second Military Medical University (SMMU), Dept. of Urology, Shanghai, China, <sup>4</sup>Peking University People's Hospital, Dept. of Urology, Beijing, China
- \*849 **Nomograms to estimate castration resistance and cancer specific survival in patients with advanced prostate cancer - GESCAP Study**  
**By:** Gómez-Veiga E.<sup>1</sup>, Rodríguez-Antolín A.<sup>2</sup>, Miñana B.<sup>3</sup>, Cozar J.M.<sup>4</sup>, Pedrosa E.<sup>5</sup>  
**Institutes:**<sup>1</sup>Hospital Universitario De Salamanca IBSAL, Dept. of Urology, Salamanca, Spain, <sup>2</sup>Hospital Universitario 12 De Octubre, Dept. of Urology, Madrid, Spain, <sup>3</sup>Hospital Morales Meseguer, Dept. of Urology, Murcia, Spain, <sup>4</sup>Hospital Universitario Virgen De Las Nieves, Dept. of Urology, Granada, Spain, <sup>5</sup>Astellas Pharma S.A., Medical Department, Madrid, Spain
- \*850 **Toremifene plus androgen deprivation therapy (TOPADT) significantly improved biochemical recurrence in bone metastatic prostate cancer: A randomized controlled phase IIA trial**  
**By:** Fujimura T.<sup>1</sup>, Takahashi S.<sup>2</sup>, Kume H.<sup>1</sup>, Urano T.<sup>3</sup>, Takayama K.<sup>3</sup>, Yamada Y.<sup>1</sup>, Suzuki M.<sup>1</sup>, Fukuhara H.<sup>1</sup>, Nakagawa T.<sup>1</sup>, Inoue S.<sup>4</sup>, Homma Y.<sup>1</sup>  
**Institutes:**<sup>1</sup>The University of Tokyo, Dept. of Urology, Tokyo, Japan, <sup>2</sup>The Nihon University, Dept. of Urology, Tokyo, Japan, <sup>3</sup>The University of Tokyo, Dept. of Geriatric Medicine, Tokyo, Japan, <sup>4</sup>The University of Tokyo, Dept. of Anti-Aging Medicine, Tokyo, Japan
- \*851 **Clinicopathological features of patients progressed into castration-resistant prostate cancer after radical prostatectomy**  
**By:** Yoo S., Han J.H., Shin J., Lee C., You D., Jeong I.G., Hong J., Ahn H., Kim C.S.  
**Institutes:**Asan Medical Center, Dept. of Urology, Seoul, South Korea
- \*852 **The impact of androgen deprivation therapy on body composition and hepatic fat content among men with prostate cancer**  
**By:** Ostergren P.B.<sup>1</sup>, Chabanova E.<sup>2</sup>, Fode M.<sup>1</sup>, Bennedbæk F.N.<sup>3</sup>, Faber J.<sup>3</sup>, Sonksen J.<sup>1</sup>, Kistorp C.<sup>3</sup>  
**Institutes:**<sup>1</sup>Herlev and Gentofte University Hospital, Faculty of Health and Medical Sciences, Copenhagen University, Dept. of Urology, Herlev, Denmark, <sup>2</sup>Herlev and Gentofte University Hospital, Faculty of Health and Medical Sciences, Copenhagen University, Dept. of Radiology, Herlev, Denmark, <sup>3</sup>Herlev and Gentofte University Hospital, Faculty of Health and Medical Sciences, Copenhagen University, Dept. of Endocrinology, Herlev, Denmark
- \*853 **Prevalence of hand joint symptoms of androgen deprivation therapy in Japanese prostate cancer patients**  
**By:** Inoue S., Kitano H., Hieda K., Shinmei S., Shoji K., Hayashi T., Teishima J., Matsubara A.  
**Institutes:**Hiroshima University, Dept. of Urology, Hiroshima, Japan
- \*854 **Fracture risk assessment of men treated with androgen deprivation therapy for prostate cancer**  
**By:** Turo R.<sup>1</sup>, Calinciuc A.<sup>1</sup>, Horsu S.<sup>1</sup>, Stephens L.<sup>1</sup>, Nikomanis P.<sup>1</sup>, Smolski M.<sup>2</sup>, Gulur D.<sup>1</sup>, Das S.<sup>1</sup>, Awsare N.<sup>1</sup>, Pettersson B.<sup>1</sup>, Sinclair A.<sup>3</sup>, Oakley N.<sup>3</sup>, Adeyoju A.<sup>3</sup>, Bromage S.<sup>3</sup>, Brown S.<sup>3</sup>, Brough R.<sup>3</sup>, Collins G.<sup>3</sup>, Cross W.<sup>4</sup>  
**Institutes:**<sup>1</sup>Countess of Chester Hospital, Dept. of Urology, Chester, United Kingdom, <sup>2</sup>Royal Preston Hospital, Dept. of Urology, Preston, United Kingdom, <sup>3</sup>Stepping Hill Hospital, Dept. of Urology, Stockport, United Kingdom, <sup>4</sup>St James's University Hospital, Dept. of Urology, Leeds, United Kingdom
- 13:30 - 13:37 **Summary and context**  
 F. Calais Da Silva Junior, Lisbon (PT)